The estimated Net Worth of Claes Glassell is at least $1.21 Million dollars as of 15 December 2008. Claes Glassell owns over 50,000 units of Cerus stock worth over $362,649 and over the last 20 years Claes sold CERS stock worth over $845,820.
Claes has made over 6 trades of the Cerus stock since 2004, according to the Form 4 filled with the SEC. Most recently Claes sold 14,097 units of CERS stock worth $845,820 on 4 December 2019.
The largest trade Claes's ever made was buying 50,000 units of Cerus stock on 15 December 2008 worth over $36,000. On average, Claes trades about 5,325 units every 200 days since 2004. As of 15 December 2008 Claes still owns at least 176,902 units of Cerus stock.
You can see the complete history of Claes Glassell stock trades at the bottom of the page.
Claes's mailing address filed with the SEC is ONE MEADOWLANDS PLAZA, , EAST RUTHERFORD, NJ, 07073.
Over the last 21 years, insiders at Cerus have traded over $5,083,598 worth of Cerus stock and bought 1,382,745 units worth $4,903,526 . The most active insiders traders include William Mariner Greenman, Laurence M Corash, and Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of $90,805. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth $178,539.
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Cerus executives and other stock owners filed with the SEC include: